173 related articles for article (PubMed ID: 3026001)
1. Sulbactam/ampicillin: in vitro spectrum, potency, and activity in models of acute infection.
Retsema JA; English AR; Girard A; Lynch JE; Anderson M; Brennan L; Cimochowski C; Faiella J; Norcia W; Sawyer P
Rev Infect Dis; 1986; 8 Suppl 5():S528-34. PubMed ID: 3026001
[TBL] [Abstract][Full Text] [Related]
2. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae, and Bacteroides.
Retsema JA; English AR; Girard AE
Antimicrob Agents Chemother; 1980 Apr; 17(4):615-22. PubMed ID: 6249192
[TBL] [Abstract][Full Text] [Related]
3. Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.
Barry AL; Jones RN; Thornsberry C
J Clin Microbiol; 1984 Feb; 19(2):134-9. PubMed ID: 6321543
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of sulbactam/ampicillin in pediatric infections caused by ampicillin-resistant or penicillin-resistant organisms.
Syriopoulou V; Bitsi M; Theodoridis C; Saroglou I; Krikos X; Tzanetou K
Rev Infect Dis; 1986; 8 Suppl 5():S630-3. PubMed ID: 3026016
[TBL] [Abstract][Full Text] [Related]
5. In vitro bactericidal activity of sulbactam plus ampicillin against methicillin-resistant Staphylococcus aureus.
Kazmierczak A; Duez JM; Pechinot A; Nordmann P; Labia R
Rev Infect Dis; 1986; 8 Suppl 5():S549-54. PubMed ID: 3026003
[TBL] [Abstract][Full Text] [Related]
6. Activity of sulbactam/ampicillin in screening and discriminative animal models of infection.
English AR; Girard D; Cimochowski C; Faiella J; Retsema JA; Lynch JE
Rev Infect Dis; 1986; 8 Suppl 5():S535-42. PubMed ID: 3026002
[TBL] [Abstract][Full Text] [Related]
7. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.
Jones RN; Barry AL
J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind comparison of sulbactam/ampicillin and clindamycin for the treatment of aerobic and aerobic-anaerobic infections.
Reinhardt JF; Johnston L; Ruane P; Johnson CC; Ingram-drake L; MacDonald K; Ward KW; Mathisen G; George WL; Finegold SM
Rev Infect Dis; 1986; 8 Suppl 5():S569-75. PubMed ID: 3026005
[TBL] [Abstract][Full Text] [Related]
9. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
[TBL] [Abstract][Full Text] [Related]
10. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
Jones RN; Barry AL; Thornsberry C; Wilson HW
Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
[TBL] [Abstract][Full Text] [Related]
11. Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.
Fuglesang JE; Bergan T
Infection; 1984; 12(1):46-50. PubMed ID: 6323321
[TBL] [Abstract][Full Text] [Related]
12. Activity of beta-lactamase inhibitor sulbactam plus ampicillin against animal isolates of Pasteurella, Haemophilus, and Staphylococcus.
Girard AE; Schelkly WU; Murphy KT; Sawyer PS
Am J Vet Res; 1987 Dec; 48(12):1678-83. PubMed ID: 3501686
[TBL] [Abstract][Full Text] [Related]
13. Synergy of sulbactam and ampicillin against methicillin-resistant staphylococci.
Chin NX; Neu NM; Neu HC
Drugs Exp Clin Res; 1986; 12(12):939-42. PubMed ID: 3032552
[TBL] [Abstract][Full Text] [Related]
14. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.
Barry AL; Jones RN
J Clin Microbiol; 1988 Apr; 26(4):750-4. PubMed ID: 3130390
[TBL] [Abstract][Full Text] [Related]
15. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.
Campoli-Richards DM; Brogden RN
Drugs; 1987 Jun; 33(6):577-609. PubMed ID: 3038500
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and safety of sulbactam/ampicillin in patients suffering from chronic liver disease.
Galante D; Esposito S; Barba D; Ruffilli MP
J Antimicrob Chemother; 1987 Apr; 19(4):527-32. PubMed ID: 3034850
[TBL] [Abstract][Full Text] [Related]
17. Sulbactam/ampicillin in the treatment of acute epiglottitis in children.
Wald E; Reilly JS; Bluestone CD; Chiponis D
Rev Infect Dis; 1986; 8 Suppl 5():S617-9. PubMed ID: 3026014
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of sulbactam combined with ampicillin against anaerobic bacteria.
Wexler HM; Harris B; Carter WT; Finegold SM
Antimicrob Agents Chemother; 1985 May; 27(5):876-8. PubMed ID: 2990330
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of sulbactam plus ampicillin in gynecologic infections.
Giamarellou H; Trouvas G; Avlami A; Aravantinos D; Daikos GK
Rev Infect Dis; 1986; 8 Suppl 5():S579-82. PubMed ID: 3026007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
